跳至主要内容
临床试验/NCT00559858
NCT00559858Unknown3 期

A Randomised Placebo-controlled Study Evaluating the Role of Pyridoxine in Controlling Capecitabine-induced Hand-foot Syndrome

Cambridge University Hospitals NHS Foundation Trust32 个研究点 分布在 1 个国家目标入组 270 人开始时间: 2004年12月最近更新:
适应症

试验速览

阶段
3 期
入组人数
270
试验地点
32
主要终点
Incidence of capecitabine dose modifications (dose delay and dose reductions) due to toxicity

研究概览

简要总结

RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome.

PURPOSE: This phase III randomized trial is studying pyridoxine to see how well it works compared to a placebo in preventing hand-foot syndrome in patients who are receiving capecitabine for advanced colorectal cancer or breast cancer.

详细描述

OBJECTIVES:

Primary

  • Determine whether pyridoxine can reduce the incidence of capecitabine dose modifications (dose delay and dose reductions) due to toxicity.

Secondary

  • Determine the incidence of hand-foot syndrome (HFS).
  • Determine the overall toxicity.
  • Determine the quality of life.
  • Determine the response to chemotherapy.
  • Determine the progression-free survival.
  • Determine the level of biomarkers which might predict the occurrence of HFS.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Supportive Care
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Incidence of capecitabine dose modifications (dose delay and dose reductions) due to toxicity

次要结局

  • Measurement of biomarkers that might predict the occurrence of HFS
  • Response to chemotherapy
  • Progression-free survival
  • Incidence of hand-foot syndrome (HFS)
  • Quality of life
  • Overall toxicity

研究者

研究点 (32)

Loading locations...

相似试验